It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

An Efficacy and Safety Trial of MK-8931 in Subjects with Prodromal Alzheimer’s Disease

Clinical Trial Title: 
An efficacy and safety trial of MK-8931 in subjects with prodromal Alzheimer’s disease
Clinical Trial Protocol ID: 
13092401
Clinical Trial Investigator Name: 
Raj C. Shah, MD
Clinical Trial Protocol Description: 

The purpose of this four-year study is to evaluate the efficacy and safety of multiple doses of an experimental drug compared to placebo, as measured by overall clinical decline and/or progression, in subjects with prodromal Alzheimer’s disease. At Rush University Medical Center, we anticipate recruiting approximately five people. Treatment or matching placebo will be assigned randomly.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 50 to 85 years of age.
  • Have been diagnosed with prodromal Alzheimer’s disease or aMCI.
  • Have a study partner willing to accompany you to all study visits.

You will be excluded from the study if any of the following criteria apply to you:

  • Are unwilling or unable to undergo multiple PET or MRI scans.
  • Have medical conditions that are not stable or that require adjustments of your medications.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Alzheimer’s Disease and Related Dementias
Contact Phone: 
(312) 942-3033
Contact Name: 
Pat Samuels